Recommendations for the management of candidemia in neonates in Latin America

Revista Iberoamericana de Micologia

Volumn 30, Issue 3, 2013, Pages 158-170

  Santolaya, María E ^a,m   Alvarado Matute, Tito ^b,m   de Queiroz Telles, Flavio ^c,m   Colombo, Arnaldo Lopes ^d,m   Zurita, Jeannete ^e,m   Tiraboschi, Iris Nora ^f,m   Cortes, Jorge Alberto ^g,m   Thompson Moya, Luis ^h,m   Guzman Blanco, Manuel ^i,m   Sifuentes, Jose ^j,m   Echevarría, Juan ^k,m   Nucci, Marcio ^l,m  

^a UNIVERSITY OF CHILE   (Chile)

^b Hospital Escuela   (Honduras)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^f HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^g UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^h UNIVERSIDAD DEL DESARROLLO   (Chile)

ⁱ Centro Medico Docente La Trinidad   (Venezuela)

^j INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^k UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^l FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^m Latin America Invasive Mycosis Network   (United States)

more..

Author keywords

Candidemia; Latin America; Management; Neonates; Recommendations

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; LACTOFERRIN; MICAFUNGIN; NYSTATIN; PLACEBO; PROBIOTIC AGENT;

AGE DISTRIBUTION; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA MENINGITIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; COST EFFECTIVENESS ANALYSIS; DEVELOPMENTAL DISORDER; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; ENDOCARDITIS; ENDOPHTHALMITIS; EXTREMELY LOW BIRTH WEIGHT; FUNGAL DETECTION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MORTALITY; NEWBORN INFECTION; NONHUMAN; OSTEOMYELITIS; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SOUTH AND CENTRAL AMERICA; TREATMENT DURATION; ALGORITHM; BRAIN DAMAGE, CHRONIC; CANDIDA; CANDIDIASIS, INVASIVE; CATHETER-RELATED INFECTIONS; CLASSIFICATION; COMPLICATION; CONSENSUS DEVELOPMENT; CROSS INFECTION; DISEASE MANAGEMENT; DISEASE PREDISPOSITION; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; INFANT, PREMATURE, DISEASES; ISOLATION AND PURIFICATION; LOW BIRTH WEIGHT; MICROBIOLOGY; NEWBORN; PRACTICE GUIDELINE; PREMATURITY;

ALGORITHMS; ANTIFUNGAL AGENTS; BRAIN DAMAGE, CHRONIC; CANDIDA; CANDIDEMIA; CANDIDIASIS, INVASIVE; CATHETER-RELATED INFECTIONS; CROSS INFECTION; DISEASE MANAGEMENT; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LATIN AMERICA; RISK FACTORS; CATHETERIZATION, CENTRAL VENOUS; COMBINED MODALITY THERAPY; DEVICE REMOVAL; DIAGNOSTIC IMAGING; ENCEPHALITIS; ENDOCARDITIS; ENDOPHTHALMITIS; FLUCONAZOLE; GESTATIONAL AGE; OSTEOMYELITIS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPECIES SPECIFICITY;

AMÉRICA LATINA; CANDIDEMIA; LATIN AMERICA; MANAGEMENT; MANEJO; NEONATES; NEONATOS; RECOMENDACIONES; RECOMMENDATIONS;

EID: 84886947659     PISSN: 11301406     EISSN: 21739188     Source Type: Journal    
DOI: 10.1016/j.riam.2013.05.012     Document Type: Article

References (104)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122-1128.
2. Aghai Z.H., Mudduluru M., Nakhla T.A., Amendolia B., Longo D., Kemble N., et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006, 26:550-555.
3. Almirante B., Rodriguez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 2007, 9:311-321.
4. Arrieta A.C., Maddison P., Groll A.H. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J 2011, 30:e97-e102.
5. Arrieta A.C., Shea K., Dhar V., Cleary J.P., Kukreja S., Morris M., et al. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study. Clin Ther 2010, 32:265-271.
6. Austin N., Darlow B.A., McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev 2009, 4:CD003478.
7. Avila-Aguero M.L., Canas-Coto A., Ulloa-Gutierrez R., Caro M.A., Alfaro B., Paris M.M. Risk factors for Candida infections in a neonatal intensive care unit in Costa Rica. Int J Infect Dis 2005, 9:90-95.
8. Aydemir C., Oguz S.S., Dizdar E.A., Akar M., Sarikabadayi Y.U., Saygan S., et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011, 96:F164-F168.
9. Aziz M., Patel A.L., Losavio J., Iyengar A., Berven M., Schloemer N., et al. Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants. Pediatr Infect Dis J 2010, 29:352-356.
10. Baley J.E., Ellis F.J. Neonatal candidiasis: ophthalmologic infection. Semin Perinatol 2003, 27:401-405.
11. Baley J.E., Kliegman R.M., Fanaroff A.A. Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics 1984, 73:153-157.
12. Baley J.E., Meyers C., Kliegman R.M., Jacobs M.R., Blumer J.L. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990, 116:791-797.
13. Benjamin D.K., DeLong E.R., Steinbach W.J., Cotton C.M., Walsh T.J., Clark R.H. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 2003, 112:543-547.
14. Benjamin D.K., Poole C., Steinbach W.J., Rowen J.L., Walsh T.J. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003, 112(3 Pt 1):634-640.
15. Benjamin D.K., Smith P.B., Arrieta A., Castro L., Sanchez P.J., Kaufman D., et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010, 87:93-99.
16. Benjamin D.K., Stoll B.J., Fanaroff A.A., McDonald S.A., Oh W., Higgins R.D., et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006, 117:84-92.
17. Bertini G., Perugi S., Dani C., Filippi L., Pratesi S., Rubaltelli F.F. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005, 147:162-165.
18. Brammer K.W., Farrow P.R., Faulkner J.K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990, 12(Suppl. 3):S318-S326.
19. Brion L.P., Uko S.E., Goldman D.L. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 2007, 54:521-529.
20. Butler K.M., Rench M.A., Baker C.J. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990, 9:51-56.
21. Chapman R.L., Faix R.G. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J 2000, 19:822-827.
22. Clerihew L., Austin N., McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2007, 4:CD003850.
23. Clerihew L., Austin N., McGuire W. Systemic antifungal prophylaxis for very low birthweight infants: a systematic review. Arch Dis Child Fetal Neonatal Ed 2008, 93:F198-F200.
24. Cotten C.M., McDonald S., Stoll B., Goldberg R.N., Poole K., Benjamin D.K. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006, 118:717-722.
25. Downey L.C., Smith P.B., Benjamin D.K., Cohen-Wolkowiez M. Recent advances in the detection of neonatal candidiasis. Curr Fungal Infect Rep 2010, 4:17-22.
26. Driessen M., Ellis J.B., Cooper P.A., Wainer S., Muwazi F., Hahn D., et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996, 15:1107-1112.
27. Faix R.G. Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J 1992, 11:88-93.
28. Fanaroff A.A. Fluconazole for the prevention of fungal infections: get ready, get set, caution. Pediatrics 2006, 117:214-215.
29. Feja K.N., Wu F., Roberts K., Loughrey M., Nesin M., Larson E., et al. Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr 2005, 147:156-161.
30. Fernandez M., Moylett E.H., Noyola D.E., Baker C.J. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000, 31:458-463.
31. Fraser V.J., Jones M., Dunkel J., Storfer S., Medoff G., Dunagan W.C. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992, 15:414-421.
32. Frattarelli D.A., Reed M.D., Giacoia G.P., Aranda J.V. Antifungals in systemic neonatal candidiasis. Drugs 2004, 64:949-968.
33. Friedman S., Richardson S.E., Jacobs S.E., O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000, 19:499-504.
34. Healy C.M., Campbell J.R., Zaccaria E., Baker C.J. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008, 121:703-710.
35. Heresi G.P., Gerstmann D.R., Reed M.D., van den Anker J.N., Blumer J.L., Kovanda L., et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006, 25:1110-1115.
36. Hitchcock R.J., Pallett A., Hall M.A., Malone P.S. Urinary tract candidiasis in neonates and infants. Br J Urol 1995, 76:252-256.
37. Hope W.W., Mickiene D., Petraitis V., Petraitiene R., Kelaher A.M., Hughes J.E., et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008, 197:163-171.
38. Hope W.W., Smith P.B., Arrieta A., Buell D.N., Roy M., Kaibara A., et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010, 54:2633-2637.
39. Huang Y.C., Lin T.Y., Lien R.I., Chou Y.H., Kuo C.Y., Yang P.H., et al. Fluconazole therapy in neonatal candidemia. Am J Perinatol 2000, 17:411-415.
40. Jeon G.W., Koo S.H., Lee J.H., Hwang J.H., Kim S.S., Lee E.K., et al. A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants. Yonsei Med J 2007, 48:619-626.
41. Johnson E.M., Warnock D.W., Luker J., Porter S.R., Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995, 35:103-114.
42. Karlowicz M.G., Hashimoto L.N., Kelly R.E., Buescher E.S. Should central venous catheters be removed as soon as candidemia is detected in neonates?. Pediatrics 2000, 106:E63.
43. Kaufman D. Neonatal candidiasis: clinical manifestations, management and prevention strategies. J Pediatr 2010, 156(4 Suppl. 2):S53-S67.
44. Kaufman D., Boyle R., Hazen K.C., Patrie J.T., Robinson M., Donowitz L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001, 345:1660-1666.
45. Kaufman D., Boyle R., Hazen K.C., Patrie J.T., Robinson M., Grossman L.B. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 2005, 147:172-179.
46. Kaufman D., Fairchild K.D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev 2004, 17:638-680.
47. Kaufman D.A. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010, 26:1769-1778.
48. Kaufman D.A., Cuff A.L., Wamstad J.B., Boyle R., Gurka M.J., Grossman L.B., et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011, 158:759-765.e1.
49. Kaufman D.A., Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants. Clin Perinatol 2010, 37:611-628.
50. Kicklighter S.D., Springer S.C., Cox T., Hulsey T.C., Turner R.B. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001, 107:293-298.
51. Law D., Moore C.B., Wardle H.M., Ganguli L.A., Keaney M.G., Denning D.W. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994, 34:659-668.
52. Leenders A.C., Daenen S., Jansen R.L., Hop W.C., Lowenberg B., Wijermans P.W., et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998, 103:205-212.
53. Levy I., Shalit I., Askenazi S., Klinger G., Sirota L., Linder N. Duration and outcome of persistent candidaemia in newborn infants. Mycoses 2006, 49:197-201.
54. Levy I., Shalit I., Birk E., Sirota L., Ashkenazi S., German B., et al. Candida endocarditis in neonates: report of five cases and review of the literature. Mycoses 2006, 49:43-48.
55. Linder N., Klinger G., Shalit I., Levy I., Ashkenazi S., Haski G., et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003, 52:663-667.
56. Manzoni P., Arisio R., Mostert M., Leonessa M., Farina D., Latino M.A., et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics 2006, 117:e22-e32.
57. Manzoni P., Farina D., Leonessa M., d'Oulx E.A., Galletto P., Mostert M., et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics 2006, 118:2359-2364.
58. Manzoni P., Leonessa M., Galletto P., Latino M.A., Arisio R., Maule M., et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008, 27:731-737.
59. Manzoni P., Stolfi I., Messner H., Cattani S., Laforgia N., Romeo M.G., et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2012, 129:116-123.
60. Manzoni P., Stolfi I., Pugni L., Decembrino L., Magnani C., Vetrano G., et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007, 356:2483-2495.
61. Marodi L. Neonatal innate immunity to infectious agents. Infect Immun 2006, 74:1999-2006.
62. McCrossan B.A., McHenry E., O'Neill F., Ong G., Sweet D.G. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed 2007, 92:F454-F458.
63. McGuire W., Clerihew L., Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2004, 1:CD003850.
64. Mohan P., Eddama O., Weisman L.E. Patient isolation measures for infants with Candida colonization or infection for preventing or reducing transmission of Candida in neonatal units. Cochrane Database Syst Rev 2007, 3:CD006068.
65. Natarajan G., Lulic-Botica M., Rongkavilit C., Pappas A., Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005, 25:770-777.
66. Neely M.N., Schreiber J.R. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics 2001, 107:404-405.
67. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617-623.
68. Noyola D.E., Fernandez M., Moylett E.H., Baker C.J. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001, 32:1018-1023.
69. Odio C.M., Araya R., Pinto L.E., Castro C.E., Vasquez S., Alfaro B., et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004, 23:1093-1097.
70. Paganini H., Rodriguez Brieshcke T., Santos P., Seu S., Rosanova M.T. Risk factors for nosocomial candidaemia: a case-control study in children. J Hosp Infect 2002, 50:304-308.
71. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
72. Pera A., Byun A., Gribar S., Schwartz R., Kumar D., Parimi P. Dexamethasone therapy and Candida sepsis in neonates less than 1250 grams. J Perinatol 2002, 22:204-208.
73. Pfaller M.A., Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002, 40:3551-3557.
74. Procianoy R.S., Eneas M.V., Silveira R.C. Empiric guidelines for treatment of Candida infection in high-risk neonates. Eur J Pediatr 2006, 165:422-423.
75. Queiroz-Telles F., Berezin E., Leverger G., Freire A., van der Vyver A., Chotpitayasunondh T., et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008, 27:820-826.
76. Ramirez Aguilar M.L., Perez Miravete A., Santos Preciado J.I. Biological features and experimental pathogenicity of Candida strains isolated by hemoculture at the Hospital Infantil de Mexico "Federico Gomez". Rev Latinoam Microbiol 1992, 34:259-265.
77. Richardson M., Warnock D.W. Laboratory diagnosis of fungal infection. Fungal Infection: Diagnosis and Management 2012, 12-30. John Wiley & Sons, Chichester, West Sussex, UK.
78. Robinson J.A., Pham H.D., Bloom B.T., Wittler R.R. Risk factors for persistent candidemia infection in a neonatal intensive care unit and its effect on mortality and length of hospitalization. J Perinatol 2012, 32:621-625.
79. Rodero L., Boutureira M., Demkura H., Burkett A., Fernandez C., Losso M., et al. Yeast infections: causative agents and their antifungal resistance in hospitalized pediatric patients and HIV-positive adults. Rev Argent Microbiol 1997, 29:7-15.
80. Rodero L., Hochenfellner F., Demkura H., Pereda R., Cordoba S., Canteros C., et al. Nosocomial transmission of Candida albicans in newborn infants. Rev Argent Microbiol 2000, 32:179-184.
81. Rodriguez D., Almirante B., Park B.J., Cuenca-Estrella M., Planes A.M., Sanchez F., et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006, 25:224-229.
82. Romeo M.G., Romeo D.M., Trovato L., Oliveri S., Palermo F., Cota F., et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 2011, 31:63-69.
83. Saez-Llorens X., Macias M., Maiya P., Pineros J., Jafri H.S., Chatterjee A., et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009, 53:869-875.
84. Saiman L., Ludington E., Pfaller M., Rangel-Frausto S., Wiblin R.T., Dawson J., et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000, 19:319-324.
85. Santolaya M.E., Queiroz-Tellez F., Nucci M. Epidemiology of candidemia in children from Latin America: a key step required to improve disease outcome. Libro de resúmenes XXIX Congreso Chileno de Infectología 2012.
86. Saxen H., Hoppu K., Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993, 54:269-277.
87. Schwarze R., Penk A., Pittrow L. Treatment of candidal infections with fluconazole in neonates and infants. Eur J Med Res 2000, 5:203-208.
88. Shiba K., Saito A., Miyahara T. Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects. Clin Ther 1990, 12:206-215.
89. Smith P.B., Walsh T.J., Hope W., Arrieta A., Takada A., Kovanda L.L., et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009, 28:412-415.
90. Stoll B.J., Gordon T., Korones S.B., Shankaran S., Tyson J.E., Bauer C.R., et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996, 129:63-71.
91. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002, 110:285-291.
92. Tiraboschi I.N., Carnovale S., Benetucci A., Fernandez N., Kurlat I., Foccoli M., et al. Candida albicans outbreak in a neonatal intensive care unit. Rev Iberoam Micol 2007, 24:263-267.
93. Triolo V., Gari-Toussaint M., Casagrande F., Garraffo R., Dageville C., Boutte P., et al. Fluconazole therapy for Candida albicans urinary tract infections in infants. Pediatr Nephrol 2002, 17:550-553.
94. Turkova A., Roilides E., Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy-is there a 'right' choice?. Curr Opin Infect Dis 2011, 24:163-171.
95. Uko S., Soghier L.M., Vega M., Marsh J., Reinersman G.T., Herring L., et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006, 117:1243-1252.
96. Venditti M. Clinical aspects of invasive candidiasis: endocarditis and other localized infections. Drugs 2009, 69(Suppl. 1):39-43.
97. Wade K.C., Benjamin D.K., Kaufman D.A., Ward R.M., Smith P.B., Jayaraman B., et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009, 28:717-723.
98. Wade K.C., Wu D., Kaufman D.A., Ward R.M., Benjamin D.K., Sullivan J.E., et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008, 52:4043-4049.
99. Wahab Mohamed W.A., Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. J Trop Pediatr 2012, 58:25-30.
100. Wazir S., Kumar P. Systemic fungal infections in neonates: current issues. J Neonatol 2005, 20.
101. Weitkamp J.H., Poets C.F., Sievers R., Musswessels E., Groneck P., Thomas P., et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998, 26:11-15.
102. Wenzel R.P. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995, 20:1531-1534.
103. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232-1239.
104. Zhang J.P., Chen C. Meta-analysis of the efficacy and safety of fluconazole in prophylaxis of fungal infection in very low birth weight infants. Zhonghua Er Ke Za Zhi 2009, 47:891-897.